A
3.48
0.08 (2.35%)
| Penutupan Terdahulu | 3.40 |
| Buka | 3.45 |
| Jumlah Dagangan | 539,977 |
| Purata Dagangan (3B) | 962,420 |
| Modal Pasaran | 666,513,984 |
| Harga / Jualan (P/S) | 92.43 |
| Harga / Buku (P/B) | 7.56 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Jul 2025 - 4 Aug 2025 |
| Margin Operasi (TTM) | -738.49% |
| EPS Cair (TTM) | -0.410 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 15.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.07% |
| Nisbah Semasa (MRQ) | 6.01 |
| Aliran Tunai Operasi (OCF TTM) | -58.95 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -28.88 M |
| Pulangan Atas Aset (ROA TTM) | -31.58% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.02% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Arbutus Biopharma Corporation | Bercampur | Menaik |
AISkor Stockmoo
-0.9
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -3.5 |
| Purata | -0.88 |
|
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.89% |
| % Dimiliki oleh Institusi | 59.38% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Foursixthree Capital Lp | 31 Mar 2025 | 2,450,421 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Jun 2025 | Pengumuman | Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus |
| 14 May 2025 | Pengumuman | Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 07 May 2025 | Pengumuman | Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 |
| 23 Apr 2025 | Pengumuman | Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |